Ascendis Pharma AS (Ascendis Pharma) is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 β/γ, an interleukin-2 variant that activates the IL-2 receptor beta/gamma (IL-2Rβ/γ) for the treatment of cancer. Ascendis Pharma utilizes its proprietary TransCon technology platform to develop its drugs. The company operates in the US, Germany and Denmark. Ascendis Pharma is headquartered in Hellerup, Denmark.
Headquarters
Denmark
Address
Tuborg Boulevard 12, Hellerup, 2900
Website
ascendispharma.dk
Telephone
45 70 222244
No of Employees
879
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ASND (NASD)
Revenue (2022)
$288.4M
421.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
17.4%
(2022 vs 2021)
Market Cap*
$8.4B
Net Profit Margin (2022)
XYZ
84.2%
(2022 vs 2021)
* As of and is in US$
Ascendis Pharma AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TransCon |
| TransCon hGH: | |
| Growth Hormone Deficiency | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Specialised Therapeutics Asia under which ST will commercialize SKYTROFATM, YORVIPATHTM, and TransCon CNP. |
| 2024 | Corporate Changes/Expansions | In January, the company launched Frazier Life Sciences of Eyconis, Inc. |
| 2023 | Contracts/Agreements | In November, the company entered into a license agreement with Teijin for development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. |
Competitor Comparison
| Key Parameters | Ascendis Pharma AS | Genmab AS | OPKO Health Inc | Nektar Therapeutics | Zealand Pharma AS |
|---|---|---|---|---|---|
| Headquarters | Denmark | Denmark | United States of America | United States of America | Denmark |
| City | Hellerup | Koebenhavn V | Miami | San Francisco | Soeborg |
| State/Province | - | - | Florida | California | - |
| No. of Employees | 879 | 2,204 | 3,930 | 137 | 253 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert Cha | Chairman | Executive Board | 2021 | 50 |
| Jan Moller Mikkelsen | President; Chief Executive Officer; Director | Executive Board | 2007 | 63 |
| Scott T. Smith | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | 49 |
| Michael Wolff Jensen | Executive Vice President; Chief Legal Officer | Senior Management | 2023 | 51 |
| Lotte Sonderbjerg | Chief Administrative Officer; Executive Vice President | Senior Management | 2023 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward